Virtual event on
The event will feature a presentation from KOL Ben Philpot, Ph.D., Associate Director of the UNC Neuroscience Center at UNC-Chapel Hill, who will discuss the gene replacement approach to treating patients with Angelman syndrome, a genetic condition that affects the nervous system and causes severe physical and learning disabilities.
The event will also feature presentations from:
-
Kimberly Goodspeed , M.D., Assistant Professor in the Departments of Pediatrics, Neurology, and Psychology at UT Southwestern, who will provide an overview of Angelman syndrome
-
Allyson Berent DVM, Dipl. ACVIM, Chief Science Officer for the
Foundation for Angelman Therapeutics , Director of theAngelman Syndrome Biomarker and Outcome Measure Consortium and Co-Director of theInternational Angelman Syndrome Research Council , who will discuss the natural history of the disease and the burden of disease as well as provide a patient and caregiver perspective
-
Ryan Butler , Ph.D., Assistant Professor in theDepartment of Psychiatry and Pediatrics at UT Southwestern, who will discuss the vectorized knockdown of UBE3A-ATS approach to treating Angelman syndrome
-
Suyash Prasad , MBBS,M.Sc ., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of R&D of Taysha, who will review the clinical development strategy for the treatment of Angelman syndrome
To register for the investor day, please click here. A live video webcast will be available in the "Events & Media" section of the Taysha corporate website. An archived version of the event will be available on the website for 60 days.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012006159/en/
Company Contact:
SVP, Corporate Communications and Investor Relations
klee@tayshagtx.com
Media Contact:
carolyn.hawley@canalecomm.com
Source: